Zydus Lifesciences is currently trading at Rs. 355.70, up by 11.85 points or 3.45% from its previous closing of Rs. 343.85 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 350.75 and ha… Read More
Zydus Lifesciences is currently trading at Rs. 376.20, up by 3.00 points or 0.80% from its previous closing of Rs. 373.20 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 375.00 and has… Read More
Image Source : PTI
Zydus Lifesciences Q4 profit declines 41% to Rs 397 cr
Pharmaceuticals firm Zydus Lifesciences Ltd on Friday reported a 41.47 per cent decline in consolidated net pro… Read More
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5% (USRLD: Epiduo Fort… Read More
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5% (USRLD: Epiduo Fort… Read More
Zydus Lifesciences is currently trading at Rs. 357.90, up by 1.15 points or 0.32% from its previous closing of Rs. 356.75 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 357.25 and has… Read More
Zydus Lifesciences is currently trading at Rs. 357.90, up by 1.15 points or 0.32% from its previous closing of Rs. 356.75 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 357.25 and has… Read More
Zydus Lifesciences is currently trading at Rs. 368.65, up by 2.85 points or 0.78% from its previous closing of Rs. 365.80 on the BSE.
zydus cadila gets tentative approval from usfda for apre… Read More
Zydus Lifesciences has launched the molecule Sitagliptin in India under the brand names Sitaglyn and Siglyn to address Type 2 diabetes in India. Sitaglyn and Siglyn will add on to a comprehe… Read More
Zydus Lifesciences is currently trading at Rs. 368.65, up by 2.85 points or 0.78% from its previous closing of Rs. 365.80 on the BSE.
zydus cadila gets tentative approval from usfda for apre… Read More
Zydus Lifesciences is currently trading at Rs. 359.30, up by 0.60 points or 0.17 % from its previous closing of Rs. 358.70 on the BSE.
The scrip opened at Rs. 359.95 and has touched a high a… Read More
Zydus Lifesciences on Tuesday said its chairman Pankaj R Patel has been appointed as a part time non-official director in the central board of the Reserve Bank of India (RBl).
The Appointmen… Read More
Zydus Lifesciences on Monday said its Rs 750 crore-share buyback offer will commence on June 23 and close on July 6.
The drug firm, earlier known as Cadila Healthcare, has fixed July 15, 202… Read More
Pharmaceuticals firm Zydus Lifesciences Ltd on Friday reported a 41.47 per cent decline in consolidated net profit at Rs 397.4 crore in the fourth quarter ended March, impacted by higher exp… Read More
Zydus Lifesciences buyback 2022 was announced on May 20, 2022. The Zydus Life buyback open date is June 23 and will close on July 6, 2022. Zydus buyback record date is June 2, 2022. The inve… Read More
Zydus Lifesciences is currently trading at Rs. 361.30, up by 4.10 points or 1.15% from its previous closing of Rs. 357.20 on the BSE.
The scrip opened at Rs. 357.50 and has touched a high an… Read More
Zydus Lifesciences is currently trading at Rs. 361.30, up by 4.10 points or 1.15% from its previous closing of Rs. 357.20 on the BSE.
The scrip opened at Rs. 357.50 and has touched a high an… Read More
Zydus Lifesciences on Wednesday reported a 13 per cent decline in consolidated net profit at Rs 518 crore for the first quarter ended June on account of lower sales in the domestic market.
T… Read More
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Sildenafil for Oral Suspension USP 10 mg/ml USRLD: Revatio.
Zydus Lifesci… Read More
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Sildenafil for Oral Suspension USP 10 mg/ml USRLD: Revatio.
Zydus Lifesci… Read More
Zydus Lifesciences is currently trading at Rs. 423.00, up by 3.00 points or 0.71% from its previous closing of Rs. 420.00 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 419.15 and has… Read More
Zydus Lifesciences is currently trading at Rs. 416.30, up by 4.90 points or 1.19% from its previous closing of Rs. 411.40 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 411.05 and has… Read More
Zydus Lifesciences is currently trading at Rs. 416.30, up by 4.90 points or 1.19% from its previous closing of Rs. 411.40 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 411.05 and has… Read More
Zydus Lifesciences is currently trading at Rs. 437.25, up by 7.75 points or 1.80% from its previous closing of Rs. 429.50 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 430.00 and has… Read More
Zydus Lifesciences is currently trading at Rs. 437.25, up by 7.75 points or 1.80% from its previous closing of Rs. 429.50 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 430.00 and has… Read More
Zydus Lifesciences Limited spends on CSR
Mumbai: In accordance with Section 8 of the 2013 Companies Act, Zydus Lifesciences Limited has created a fully owned subsidiary to undertake CSR. The… Read More
Zydus Lifesciences is currently trading at Rs. 410.85, up by 1.40 points or 0.34% from its previous closing of Rs. 409.45 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 411.05 and has… Read More
Zydus Lifesciences is currently trading at Rs. 410.85, up by 1.40 points or 0.34% from its previous closing of Rs. 409.45 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 411.05 and has… Read More
Zydus Lifesciences on Friday said it has received approval from the US health regulator to market Estradiol Transdermal System, used to treat moderate to severe symptoms of menopause, in the… Read More
New Delhi, Dec 2: Zydus Lifesciences on Friday said it has received approval from the US health regulator to market Estradiol Transdermal System, used to treat moderate to severe symptoms of… Read More
Securities has buy call on Zydus Lifesciences with a target price of Rs 488. The current market price of is Rs 456.2. HDFC Securities recommended to keep stoploss at Rs…
This News Bu… Read More
Zydus Lifesciences Ltd on Tuesday said it has received final approval from the US health regulator to market its generic version of Febuxostat tablets used to treat high uric acid in the blo… Read More
Zydus Lifesciences Ltd on Friday reported a 24.48 per cent rise in consolidated net profit at Rs 622.9 crore for the third quarter ended December 31, 2022.
The company had posted a consol… Read More
HiveMinds, a leading digital marketing agency and the digital specialist of Madison World, further establishes its leadership position by winning mandates for some of the leading brands. The… Read More
Zydus Lifesciences is currently trading at Rs. 469.30, up by 3.75 points or 0.81% from its previous closing of Rs. 465.55 on the BSE.
Zydus LifesciencesThe scrip opened at Rs. 469.95 and has… Read More
Zydus Lifesciences is currently trading at Rs. 478.75, up by 2.90 points or 0.61% from its previous closing of Rs. 475.85 on the BSE.
The scrip opened at Rs. 474.00 and has touched a high a… Read More
Zydus Lifesciences is currently trading at Rs. 478.75, up by 2.90 points or 0.61% from its previous closing of Rs. 475.85 on the BSE.
The scrip opened at Rs. 474.00 and has touched a high a… Read More
Ahmedabad: Zydus Lifesciences Limited’s subsidiary Zydus Pharmaceuticals (USA) Inc. has received final approval for Tofacitinib Tablets, 5 mg and tentative approval for Tofacitinib Tab… Read More
Zydus Lifesciences is currently trading at Rs. 483.20, up by 4.65 points or 0.97% from its previous closing of Rs. 478.55 on the BSE.
The scrip opened at Rs. 478.60 and has touched a high a… Read More
Zydus Lifesciences is currently trading at Rs. 483.20, up by 4.65 points or 0.97% from its previous closing of Rs. 478.55 on the BSE.
The scrip opened at Rs. 478.60 and has touched a high a… Read More
Zydus Lifesciences is currently trading at Rs. 483.15, up by 0.80 points or 0.17% from its previous closing of Rs. 482.35 on the BSE.
The scrip opened at Rs. 480.35 and has touched a high a… Read More
Zydus Lifesciences is currently trading at Rs. 483.15, up by 0.80 points or 0.17% from its previous closing of Rs. 482.35 on the BSE.
The scrip opened at Rs. 480.35 and has touched a high a… Read More
Zydus Lifesciences is currently trading at Rs. 507.55, up by 3.90 points or 0.77% from its previous closing of Rs. 503.65 on the BSE.
The scrip opened at Rs. 505.05 and has touched a high an… Read More
Zydus Lifesciences is currently trading at Rs. 507.55, up by 3.90 points or 0.77% from its previous closing of Rs. 503.65 on the BSE.
The scrip opened at Rs. 505.05 and has touched a high an… Read More
Ahmedabad: Drugmaker, Zydus Lifesciences Limited, has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Isoproterenol Hydrochlorid… Read More
Ahmedabad: Pharma major, Zydus Lifesciences Limited, has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and… Read More
Ahmedabad: Drugmaker, Zydus Lifesciences Limited, has recently announced that the company has received final approval from the United States Food and Drug Administration (USFDA) for Icosapen… Read More
Ahmedabad: Pharma major, Zydus Lifesciences Limited, has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and… Read More
Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to manufacture and market its generic Roflumilast tablets used in reducing inflammation i… Read More
Ahmedabad: Zydus Lifesciences Limited has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) for Minocycline Hydrochlorid… Read More
Ahmedabad-based Zydus Lifesciences has bought a 6.5% stake in biotech firm Mylab Discovery Solutions from Rising Sun Holdings Pvt Ltd, an investment company owned by Adar Poonawalla.Zydus ac… Read More
Nuvama downgrades Zydus to ‘hold’. It says Q1 results are unlikely to be repeated, as exclusivity of epilepsy drug Trokendi is declining and revenue from blood cancer drug Revlim… Read More
Zydus Lifesciences on Thursday said it has received approval from the US health regulator to market a generic product to treat acne in the American market.
The drug firm has received fina… Read More
In the ever-evolving world of stock market investments, it’s crucial to keep an eye on the latest developments. Here are some key updates on stocks that could impact your investment d… Read More
New Delhi: A unit of Zydus Lifesciences is recalling over 7,000 bottles of Oxybutynin Chloride tablets in the US due to manufacturing issues, according to the US Food and Drug Administr… Read More
New York, New York--(Newsfile Corp. - October 14, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporat… Read More
New York, New York--(Newsfile Corp. - October 19, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporat… Read More
New York, New York--(Newsfile Corp. - October 23, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporat… Read More
Law enforcement and public health officials say a surge in counterfeit versions of drugs that help with weight loss like semaglutide (Ozempic, Wegovy) may be the worst since counterfeit er… Read More